SCHEMBL3489640

SCHEMBL3489640

O=C1N(Cc2ccccc2)c2cc(Cl)cc(Cl)c2S(=O)(=O)N1Cc1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
LMNA P02545 2/20 0.49
TP53 P04637 1/20 0.48
TDP1 Q9NUW8 1/20 0.43
KMT2A Q03164 6/20 0.43
MEN1 O00255 3/20 0.43
CASP6 P55212 1/20 0.43
CYP1A2 P05177 1/20 0.42
GAA P10253 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ATM Q13315 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 2/20 0.41
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489133 0.94 F2 (0.42) MAPTLMNATP53KMT2AMEN1
SCHEMBL3489294 0.91 CA12 (0.43) MAPTLMNATP53KMT2AMEN1
SCHEMBL3490467 0.90 MAPT (0.41) MAPTLMNATP53KMT2AMEN1
SCHEMBL3489424 0.90 CA12 (0.46) MAPTLMNATP53KMT2AMEN1
SCHEMBL3490169 0.90 CA12 (0.46) MAPTLMNATP53TDP1KMT2A
SCHEMBL3488593 0.90 MAPT (0.47) MAPTLMNATP53KMT2ACYP1A2
SCHEMBL3489926 0.87 MAPT (0.38) MAPTLMNATP53KMT2AMEN1
SCHEMBL3491531 0.87 CA12 (0.43) MAPTLMNATP53HTTALDH1A1
SCHEMBL3489625 0.87 CA12 (0.43) MAPTTP53ALDH1A1
SCHEMBL3489209 0.87 MAPT (0.38) MAPTLMNATP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D MAPT 2158/4885LMNA 4446/4885TP53 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.